Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa
childhood mortality
Male
Malawi
nevirapine
HIV Infections
preschool child
310
Severity of Illness Index
South Africa
0302 clinical medicine
sensitivity analysis
Risk Factors
Antiretroviral Therapy, Highly Active
Child
Southern
Mozambique
child
lopinavir plus ritonavir
article
Age Factors
efavirenz
Human immunodeficiency virus infected patient
Prognosis
3. Good health
female
priority journal
risk factor
Child, Preschool
Female
Zimbabwe
Anti-HIV Agents
Antiretroviral Therapy
CD4 lymphocyte percentage
Africa, Southern
03 medical and health sciences
male
Human immunodeficiency virus infection
follow up
Humans
Highly Active
human
Preschool
Infant
school child
lamivudine plus stavudine
infant
major clinical study
CD4 Lymphocyte Count
adolescent
Africa
DOI:
10.1097/qai.0b013e3181e0c4cf
Publication Date:
2010-06-29T07:37:04Z
AUTHORS (16)
ABSTRACT
Many HIV-infected children in Southern Africa have been started on antiretroviral therapy (ART), but loss to follow up (LTFU) can be substantial. We analyzed mortality in children retained in care and in all children starting ART, taking LTFU into account.Children who started ART before the age of 16 years in 10 ART programs in South Africa, Malawi, Mozambique, and Zimbabwe were included. Risk factors for death in the first year of ART were identified in Weibull models. A meta-analytic approach was used to estimate cumulative mortality at 1 year.Eight thousand two hundred twenty-five children (median age 49 months, median CD4 cell percent 11.6%) were included; 391 (4.8%) died and 523 (7.0%) were LTFU in the first year. Mortality at 1 year was 4.5% [95% confidence interval (CI): 2.8% to 7.4%] in children remaining in care, but 8.7% (5.4% to 12.1%) at the program level, after taking mortality in children and LTFU into account. Factors associated with mortality in children remaining in care included age [adjusted hazard ratio (HR) 0.37; 95% CI: 0.25 to 0.54 comparing > or =120 months with <18 months], CD4 cell percent (HR: 0.56; 95% CI: 0.39 to 0.78 comparing > or =20% with <10%), and clinical stage (HR: 0.12; 95% CI: 0.03 to 0.45 comparing World Health Organization stage I with III/IV).In children starting ART and remaining in care in Southern Africa mortality at 1 year is <5% but almost twice as high at the program level, when taking LTFU into account. Age, CD4 percentage, and clinical stage are important predictors of mortality at the individual level.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (29)
CITATIONS (79)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....